YU35996A - Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže - Google Patents

Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže

Info

Publication number
YU35996A
YU35996A YU35996A YU35996A YU35996A YU 35996 A YU35996 A YU 35996A YU 35996 A YU35996 A YU 35996A YU 35996 A YU35996 A YU 35996A YU 35996 A YU35996 A YU 35996A
Authority
YU
Yugoslavia
Prior art keywords
primatized
monkey
monoclonal antibodies
antibodies
human
Prior art date
Application number
YU35996A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
R. Anderson Darrell
Brams Peter
Hanna Nabic
S. Shestowsky William
Original Assignee
Idec Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corporation filed Critical Idec Pharmaceuticals Corporation
Publication of YU35996A publication Critical patent/YU35996A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
YU35996A 1995-06-07 1996-06-07 Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže YU35996A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/487,550 US6113898A (en) 1995-06-07 1995-06-07 Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies

Publications (1)

Publication Number Publication Date
YU35996A true YU35996A (sh) 1998-12-23

Family

ID=23936199

Family Applications (1)

Application Number Title Priority Date Filing Date
YU35996A YU35996A (sh) 1995-06-07 1996-06-07 Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže

Country Status (24)

Country Link
US (4) US6113898A (cg-RX-API-DMAC7.html)
EP (2) EP1914301A1 (cg-RX-API-DMAC7.html)
JP (1) JP4242451B2 (cg-RX-API-DMAC7.html)
KR (1) KR100496307B1 (cg-RX-API-DMAC7.html)
CN (2) CN100379855C (cg-RX-API-DMAC7.html)
AR (2) AR001288A1 (cg-RX-API-DMAC7.html)
AT (1) ATE384125T1 (cg-RX-API-DMAC7.html)
AU (1) AU707023B2 (cg-RX-API-DMAC7.html)
BR (1) BR9609035A (cg-RX-API-DMAC7.html)
CA (1) CA2223532C (cg-RX-API-DMAC7.html)
CO (1) CO4480111A1 (cg-RX-API-DMAC7.html)
DE (1) DE69637408T2 (cg-RX-API-DMAC7.html)
DK (1) DK0837927T3 (cg-RX-API-DMAC7.html)
ES (1) ES2301169T3 (cg-RX-API-DMAC7.html)
IL (1) IL122370A (cg-RX-API-DMAC7.html)
MY (1) MY136224A (cg-RX-API-DMAC7.html)
NO (1) NO328554B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ311904A (cg-RX-API-DMAC7.html)
PT (1) PT837927E (cg-RX-API-DMAC7.html)
SA (1) SA96170473B1 (cg-RX-API-DMAC7.html)
UY (1) UY24256A1 (cg-RX-API-DMAC7.html)
WO (1) WO1996040878A1 (cg-RX-API-DMAC7.html)
YU (1) YU35996A (cg-RX-API-DMAC7.html)
ZA (1) ZA964547B (cg-RX-API-DMAC7.html)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
DE69739725D1 (de) * 1996-11-08 2010-02-11 Biogen Idec Inc Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)
AU8800598A (en) * 1997-06-20 1999-01-04 Innogenetics N.V. B7-binding molecules for treating immune diseases
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
NZ514914A (en) 1999-05-07 2004-09-24 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
CA2379274A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
SE9903895D0 (sv) * 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
CA2404365A1 (en) 2000-03-31 2001-10-11 Idec Pharmaceutical Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
US6379900B1 (en) 2000-05-09 2002-04-30 Conceptual Mindworks, Inc. Compositions and methods of use of 8-nitroguanine
IL152316A0 (en) * 2000-06-09 2003-05-29 Bristol Myers Squibb Co Pharmaceutical compositions and kits for treating transplant rejection
EP2052742A1 (en) 2000-06-20 2009-04-29 Biogen Idec Inc. Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
SI1372696T1 (sl) 2000-07-03 2008-12-31 Bristol Myers Squibb Co Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
MXPA03002262A (es) * 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US6955717B2 (en) * 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
US7304033B2 (en) * 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
CA2467363A1 (en) 2001-11-16 2003-06-12 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US20040009169A1 (en) 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
EP3254673A1 (en) 2002-11-13 2017-12-13 The UAB Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
JP2007501243A (ja) * 2003-08-04 2007-01-25 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法
JP4745972B2 (ja) * 2003-10-21 2011-08-10 メルク セローノ ソシエテ アノニム クロマチンインスレーターとして作用する極小ｄｎａ配列、及びタンパク質発現におけるその使用
US20070212301A1 (en) * 2003-11-07 2007-09-13 Amgen, Inc. Monkey Immunoglobulin Sequences
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN100369931C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人b7-1分子单克隆抗体及其应用
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
DK2769729T3 (en) 2007-09-04 2019-04-23 Compugen Ltd POLYPEPTIDES AND POLYNUCLEOTIDES AND APPLICATIONS THEREOF AS A PHARMACEUTICAL OBJECTIVE FOR THE PRODUCTION OF MEDICINAL PRODUCTS AND BIOTECHNOLOGICAL PRODUCTS
ES2836128T3 (es) 2008-04-16 2021-06-24 Univ Johns Hopkins Método para determinar variantes del receptor de andrógenos en cáncer de próstata
SI2483304T1 (sl) 2009-09-29 2016-08-31 F. Hoffmann-La Roche Ag Predfiltracijsko naravnavanje pufrskih snovi za močno koncentriran imunoglobulinski pripravek
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
CA2790203C (en) 2010-02-19 2019-05-14 Norman Latov Inhibitor of macrophage scavenger receptor 1 (msr1) for the treatment of autoimmune demyelinating diseases
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
GEP201706660B (en) 2010-03-04 2017-04-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
MX347734B (es) 2010-06-14 2017-05-11 Lykera Biomed Sa Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
JP5972871B2 (ja) 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｉｌ−２３ヘテロ二量体特異的抗体
PT3722808T (pt) 2010-10-25 2024-12-09 Biogen Ma Inc Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam
JP2014505462A (ja) 2010-11-10 2014-03-06 ラボラトリオス・デル・ドクター・エステベ・ソシエテ・アノニム 高免疫原性のｈｉｖｐ２４配列
ES2847304T3 (es) 2011-01-17 2021-08-02 Lykera Biomed S A Anticuerpos contra la proteína S100P para el tratamiento y diagnóstico de cáncer
WO2012100835A1 (en) 2011-01-28 2012-08-02 Laboratorios Del Dr. Esteve, S.A. Methods and compositions for the treatment of aids
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2836373A1 (en) 2011-06-06 2012-12-13 Neotope Biosciences Limited Mcam antagonists and methods of treatment
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
EP2771351B1 (en) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1 epitopes and methods for using same
WO2013114367A2 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
MX2015010023A (es) 2013-02-01 2017-11-17 Transbio Ltd Anticuerpos anti-cd83 y su uso.
PL2953971T3 (pl) 2013-02-07 2023-07-03 Csl Limited Białka wiążące il-11r i ich zastosowania
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
CN105682662A (zh) 2013-03-14 2016-06-15 马里兰大学巴尔的摩校区 雄激素受体减量调节剂及其用途
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CN105873950A (zh) 2013-04-09 2016-08-17 莱克尔生物医学有限公司 用于治疗和诊断癌症的抗s100a7抗体
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP2876114A1 (en) 2013-11-25 2015-05-27 Consejo Superior De Investigaciones Científicas Antibodies against CCR9 and applications thereof
EP3074038B1 (en) 2013-11-28 2019-01-02 CSL Limited Method of treating diabetic nephropathy
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
ES2851386T3 (es) 2013-12-18 2021-09-06 Csl Ltd Método de tratamiento de las heridas
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
JP2017523207A (ja) * 2014-08-08 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用
CA2959336A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
AU2015336931B2 (en) 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
HK1253533A1 (zh) 2015-11-27 2019-06-21 Csl Limited Cd131结合蛋白及其应用
CN105628935A (zh) * 2016-03-01 2016-06-01 广东医学院附属医院 一种检测人尿中cd80的试剂盒
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
KR20190052027A (ko) 2016-09-23 2019-05-15 씨에스엘 리미티드 응고 인자 결합 단백질 및 이의 용도
KR101926834B1 (ko) 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
US20200033347A1 (en) 2017-04-18 2020-01-30 Universite Libre De Bruxelles Biomarkers And Targets For Proliferative Diseases
LT3681911T (lt) 2017-09-11 2025-01-10 Monash University Žmogaus trombino receptorių par4 surišantys baltymai
KR102715492B1 (ko) 2017-10-18 2024-10-11 씨에스엘 리미티드 인간 혈청 알부민 변이체 및 이의 용도
CA3088676A1 (en) 2018-03-23 2019-09-26 Universite Libre De Bruxelles Wnt signaling agonist molecules
AU2019268410B2 (en) 2018-05-16 2025-01-02 Csl Limited Soluble complement receptor type 1 variants and uses thereof
BR112020025504A2 (pt) * 2018-06-22 2021-03-16 Junten Bio Co., Ltd. Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido
WO2020116636A1 (ja) * 2018-12-07 2020-06-11 小野薬品工業株式会社 免疫抑制剤
US20240368259A1 (en) 2020-07-17 2024-11-07 Onena Medicines, S.L. Antibodies against lefty proteins
WO2023089131A1 (en) 2021-11-19 2023-05-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025171411A1 (en) 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4777245A (en) * 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5045469A (en) * 1988-10-27 1991-09-03 Mycogen Corporation Novel bacillus thuringiensis isolate denoted B. T. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5304635A (en) * 1990-03-12 1994-04-19 University Of Southern California Antigen specifically expressed on the surface of B cells and Hodgkin's cells
US5521288A (en) * 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
CA2110518C (en) * 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
RO116404B1 (ro) 1991-07-25 2001-01-30 Idec Pharmaceuticals Corp San Anticorp recombinant, acid nucleic care il codifica, procedeu de obtinere a anticorpului recombinant si metoda de tratament cu acesta
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
WO1994028912A1 (en) 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
IL110855A (en) 1993-09-02 1999-04-11 Dartmouth College Methods for inducing antigen-specific t cell tolerance
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE69739725D1 (de) 1996-11-08 2010-02-11 Biogen Idec Inc Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40

Also Published As

Publication number Publication date
NO975598D0 (no) 1997-12-03
SA96170473B1 (ar) 2005-07-31
NO975598L (no) 1998-02-09
AR053814A2 (es) 2007-05-23
EP1914301A1 (en) 2008-04-23
US6709654B1 (en) 2004-03-23
UY24256A1 (es) 1996-06-18
DE69637408T2 (de) 2009-01-15
BR9609035A (pt) 1999-07-06
ATE384125T1 (de) 2008-02-15
EP0837927A1 (en) 1998-04-29
PT837927E (pt) 2008-04-28
AU6331296A (en) 1996-12-30
WO1996040878A1 (en) 1996-12-19
US20010024648A1 (en) 2001-09-27
EP0837927B1 (en) 2008-01-16
KR100496307B1 (ko) 2005-11-25
AU707023B2 (en) 1999-07-01
AR001288A1 (es) 1997-10-08
US20050129688A1 (en) 2005-06-16
CN1192779A (zh) 1998-09-09
CA2223532C (en) 2010-11-09
HK1015413A1 (en) 1999-10-15
DE69637408D1 (de) 2008-03-06
EP0837927A4 (en) 2000-01-05
ZA964547B (en) 1997-01-24
JPH11508764A (ja) 1999-08-03
ES2301169T3 (es) 2008-06-16
IL122370A0 (en) 1998-06-15
NZ311904A (en) 1999-09-29
KR19990022650A (ko) 1999-03-25
DK0837927T3 (da) 2008-05-13
CA2223532A1 (en) 1996-12-19
CO4480111A1 (es) 1997-07-09
NO328554B1 (no) 2010-03-22
CN101367877A (zh) 2009-02-18
US6113898A (en) 2000-09-05
US6893638B2 (en) 2005-05-17
CN100379855C (zh) 2008-04-09
JP4242451B2 (ja) 2009-03-25
IL122370A (en) 2000-07-26
MY136224A (en) 2008-08-29
US7323170B2 (en) 2008-01-29

Similar Documents

Publication Publication Date Title
YU35996A (sh) Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže
DK0627002T3 (da) Kloning og ekspression af humaniserede monoklonale antistoffer mod human interleukin-4
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
EP1174440A1 (en) A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
AR003423A1 (es) Anticuerpos monoclonales humanos de alta afinidad especificos de la proteina- f del rsv, celulas eucarioticas transfectadas; secuencia de adn y vector de expresion que lo codifican; metodo que utiliza los anticuerpos; una composicion farmaceutica que los contiene; metodo para detectar rsv y un kit de ensayo.
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
US8748173B2 (en) Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof
EP1527100A4 (en) HUMAN MONOCLONAL ANTIBODIES TO INTERLEUKIN-5 AND THESE COMPREHENSIVE METHODS AND COMPOSITIONS
BG101841A (bg) Инхибитори на клетъчна адхезия
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
BRPI0511782A (pt) anticorpos anti-cd3 e métodos de uso dos mesmos
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ES2127531T3 (es) Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales.
MA59827B1 (fr) Anticorps anti-pd-1
Welschof et al. The antigen binding domain of non-idiotypic human anti-F (ab′) 2 autoantibodies: study of their interaction with IgG hinge region epitopes
Waldor et al. Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody.
Forni et al. Expression of V-region-like determinants on Ig-negative precursors in murine fetal liver and bone marrow
Gearhart Non-sequential expression of multiple immunoglobulin classes by isolated B-cell clones
DK0667781T3 (da) Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier
MX9709541A (es) Anticuerpos monoclonales de mono, especificos para las formas primatizadas de b7.1 y/o b7.2 humanos y composiciones farmaceuticas.
Dehghanpisheh et al. Retrovirally induced mouse anti‐TCR monoclonals can synergize the in vitro proliferative T cell response to bacterial superantigens
Rocca-Serra et al. The limited diversity of the mouse gamma-chains anti-GAT repertoire does not seem to be noticeably amplified upon class switch.
Claflin Clonal nature of the immune response to phosphorylcholine. VIII. Evidence that antibodies bearing T15 idiotypic determinants in Igh j mice comprise a family of antibodies.
Gratecos et al. A new approach to monoclonal antibody production In vitro immunization with antigens on nitrocellulose using Drosphila myosin heavy chain as an example
Ju et al. The B cell immune response to an idiotype-inducing peptide epitope can be inhibited by immunodominance of a neighboring epitope